Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts

Clinical Cancer Research

Volumn 4, Issue 12, 1998, Pages 3077-3082

  Colbern, Gail T ^a   Dykes, Donald J ^b   Engbers, Charles ^a   Musterer, Randy ^a   Hiller, Alan ^a   Pegg, Erik ^a   Saville, Renee ^a   Weng, Steve ^a   Luzzio, Michael ^c   Uster, Paul ^a   Amantea, Michael ^a   Working, Peter K ^a  

^a ALZA CORPORATION   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; GL 147211C; LIPOSOME; LURTOTECAN; MACROGOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; COLON TUMOR; CYTOPATHOGENIC EFFECT; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG UPTAKE; ENCAPSULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TARGET CELL DESTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HT29 CELLS; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 17444405966     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Dancey, J., and Eisenhauer, E. A. Current perspectives on camptothecins in cancer treatment. Br. J. Cancer, 74: 327-338, 1996.
2. Besterman, J. M. Topoisomerase I inhibition by the camptothecin analog GI147211C: from the laboratory to the clinic. Ann. N. Y. Acad. Sci., 803: 202-209, 1996.
3. Takimoto, C. H., and Arbuck, S. G. The camptothecins. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, Ed. 2, pp. 463-484. Philadelphia: Lippincott-Raven Publishers, 1996.
4. Hsiang, Y-H., Lihou, M. G., and Lui, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
5. Gerrits, C. J., de Jonge, M. J., Schellens, J. H., Stoter, G., and Verweij, J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer, 76: 952-962, 1997.
6. Luzzio, M. J., Besterman, J. M., Emerson, D. L., Evans, M. G., Lackey, K., Leitner, P. L., Mclntyre, G., Morton, B., Myers, P. L., Peel, M., Sisco, J. M., Sternback, D. D., Tong, W-Q., Truesdale, A., Uchling, D. E., Vuong, A., and Yates, J. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J. Med. Chem., 38: 395-401, 1995.
7. Gerrits, C. J., Creemers, G. J., Schellens, J. H., Wissel, P., Planting, A. S., Kunka, R., Selinger, K., deBoer-Dennert, M., Marijnen, Y., and Venveij, J. Phase I and pharmacological study of the new topoisomerase I inhibitor GL147211, using a daily X 5 intravenous administration. Br. J. Cancer, 73: 744-750, 1996.
8. Eckhardt, J. R., Rodriguez, G. I., Bums, H. A., Wissel, P. S., Fields, S. M., Rothenberg, M. L., Smith, L., Thurman, A., Kunka, R. L., Depee, S. P., Littlefield, D., White, L. J., and Von Hoff, D. D. A Phase I and pharmacokinetic study of the topoisomerase I inhibitor GG211. Proc. Am. Soc. Clin. Oncol., 14: 476, 1995.
9. Eckhardt, S. G., Baker, S. D., Eckhardt, J. R., Burke, T. G., Warner, D. L., Kuhn, J. G., Rodriguez, G., Fields, S., Thurman, A., Smith, L., Rothenberg, M. L., White, L., Wissel, P., Kunka, R., DePee, S., Littlefield, D., Bums, H. A., Von Hoff, D. D., and Rowinsky, E. K. Phase I and pharmacokinetic study of GL147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clin. Cancer Res., 4: 595-604, 1998.
10. O'Dwyer, P., Cassidy, J., Kunka, R., Pas-Arez, L., Kaye, S., Depee, S., Littlefield, D., Demaria, D., Sclinger, K., Beranek, P., Collis, P., and Wissel, P. Phase I trial of GG211, a new topoisomerase inhibitor, using a 72 hour continuous infusion. Proc. Am. Soc. Clin. Oncol., 14: 471, 1995.
11. Gabizon, A., Barenholz, Y., and Bialer, M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res. (N. Y.), 10: 703-708, 1993.
12. Gabizon, A., Catanc, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54: 987-992, 1994.
13. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464, 1991.
14. Gabizon, A., and Papahadjopoulos, D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA, 85: 6949-6953, 1988.
15. Woodle, M. C., Newman, M. S., and Working, P. K. Biological Properties of Sterically Stabilized Liposomes, pp. 103-117. Boca Raton, FL: CRC Press, 1995.
16. Working, P. K., Newman, M. S., Huang, S. K., Mayhew, E., Vaage, J., and Lasic, D. D. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (DOXIL). J. Liposome Res., 4: 667-687, 1994.
17. Working, P. K., and Dayan, A. D. Pharmacological-texicological expert report. CAELYX™ (Stealth® liposomal doxorubicin HC1). Hum. Exp. Toxicol., 75: 752-785, 1996.
18. Stafford, C. G., and St. Claire, R. L. High-performance liquid Chromatographie analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211C) in plasma. J. Chromatogr. B, 663: 119-126, 1995.
19. Emerson, D. L., Amirgahari, N., Bendele, R., Brown, E., Chen, L-S., Chiang, S-M., Gill, S., LeRay, J. D., Moynihan, K., Tomkinson, B., and Luzzio, M. J. NX-211, a liposomal formulation of Lurtotecan, demonstrates enhanced pharmacokinetic and antitumor activity. Proc. Am. Assoc. Cancer Res., 39: 278, 1998.